Abstract CT138: NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing BRCA1 and BRCA2 mutations
Year: 2019
Type: conference-abstract
Source: Cancer Research
Authors: Shivaani Kummar, Shuli Li, Kim Reiss, James M. Ford, Edith P. Mitchell, James A. Zwiebel, Naoko Takebe, Robert J. Gray, Lisa M. McShane, Larry V. Rubinstein, David Patton, Paul Mickey Williams, Stanley R. Hamilton, Adam Brufsky, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Institutions: Stanford University, University of Pittsburgh, Thomas Jefferson University Hospital, National Cancer Institute, Dana-Farber Cancer Institute, Frederick National Laboratory for Cancer Research, The University of Texas MD Anderson Cancer Center, The University of Texas Southwestern Medical Center, University of Pennsylvania, Massachusetts General Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2954549450